The pearl in this ''neuropathic'' pain patient, studied by Jørum et al., is activation of three nociceptors in hyperalgesic skin by reflex sympathetic maneuvers and by ID norepinephrine. What does it mean?
The medical nature of this patient. For the authors, this chronic pain patient has ''SMP'', a condition which ''is first and foremost associated with CRPS''. The reader wants to know what kind of ''CRPS''. Was there nerve pathology? This is impossible to resolve because the clinical description is incomplete. Burning pain was reported in peroneal nerve territories, but neurological examination did not include motor system or reflexes; motor nerve conductions were normal and the electromyogram did not show signs of muscle denervation. Moreover, the area of subjective hyperalgesia was in bilateral stocking; no sensory deficits are described; sensory nerve conduction was normal (correcting for a 1.5°C cooler left leg) and subjective thermal thresholds by QST were non-specifically impaired. Thus, a case cannot be made for neuropathy (nor peripheral inflammation). Could this be a pure small caliber fiber neuropathy? Unlikely because, in acute local compression syndromes, the primary nerve lesion spares small caliber fibers (Ochoa et al., 1971) . In sum, the cause of the patientÕs symptom complex is not known. Therefore, he officially fits ''CRPS I'', a concept disabled by nonsequitur, particularly in its criterion #4, one that evades refutability principle when it states: ''This diagnosis is excluded by the existence of conditions that would otherwise account for the degree of pain and dysfunction'' (see Ochoa and Verdugo, 2001 ). The enlightened scholar invited to introduce the latest book on CRPS, edited by Wilson et al. (2005) wrote: ''The fourth criterion says that CRPS is a diagnosis that can only be made when another diagnosis cannot be established. This means that if we get better at diagnosing something else, we will reduce the frequency of diagnosing CRPS. Either this entity exists on its own criteria, or it does not and is just a repository for patients who cannot be adequately assessed and labeled '' (Loeser, 2005) . But there must exist a testable medical explanation for this patientÕs non-specific symptoms. It will not be found unless differential diagnosis is pursued (Ochoa, 2006) . The authors did not. It might even be an ill-characterized, structurally-based peripheral neuropathy.
The clinical ''SMP''. As per the shallow criterion: ''SMP are all pain syndromes that can be relieved by sympathetic blockade' ' (Treede et al., 1991) , this patient qualified as his pain complaint was eliminated for 1 1 2 -21 days following various blocks. But in absence of placebo control, the SMP assumption is scientifically invalid because too many chronic pain patients communicate temporary relief that is demonstrably due to inert or active placebo effect (Verdugo and Ochoa, 1994a; Verdugo et al., 1994; Jadad et al., 1995; Ramamurthy and Hoffman, 1995; etc.) and recent work ratifies this (unpublished) . At the beginning of Introduction, Jørum et al. make a statement that misrepresents cited publications. They write: ''the validity of placebo-controlled studies has been questioned''. No, what those articles did question, two of them already in their title, is the concept of sympathetically maintained pain itself (Verdugo and Ochoa, 1994a; Verdugo et al., 1994) . In the present case, there was no placebo control for the phentolamine or the guanethidine blocks. Thus, if SMP exists as a pathophysiological entity, there is no evidence that this patient has it, and he could not possibly if he does not harbor neuropathy.
Psychophysical evidence of catecholamine dependence of this patientÕs sensory symptoms. Having adjudicated medical veracity to ''SMP'', gratis, Jørum et al. briefly analyze prior contradictory publications where (unlike normal volunteers) some patients, with or without prior sympathectomy, labeled with ''CRPS-SMP'' in absence of rigorous scientific evidential basis, self-reported subjective local pain from ID injection of catecholamines. But there was no placebo/nocebo control and patients of this kind express those twice as frequently as normals (Verdugo and Ochoa, 1994b) , and a recent article reports absence of catecholamine-evoked pain in painful polyneuropathy (Schattschneider et al., 2006) . Contrary to Ali et al. (2000) , one publication mentions self-reported pain following ID catecholamines in the asymptomatic contralateral side (Mailis-Gagnon and Bennett, 2004) . Imaginative theories attempt to explain remote spread of pain in ''RSD/CRPS I/SMP'' on the basis of 
